Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Non-invasive Chromosomal Examination of Trisomy Study (NEXT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01511458
Recruitment Status : Completed
First Posted : January 18, 2012
Last Update Posted : July 14, 2014
Perinatal Quality Foundation: Nuchal Translucency Quality Review
Information provided by (Responsible Party):
Roche Sequencing Solutions

Brief Summary:

The purpose of this blinded, multi-center, prospective, case-controlled study is to compare the Ariosa Harmony™ Prenatal Test for trisomy 21 detection with a standard first-trimester prenatal screening test consisting of serum screening (PAPP-A,free beta-hCG [β-hCG] or total hCG) and a nuchal translucency (NT) measurement (i.e. combined first trimester screening) in a general screened population.

The performance characteristics of these two test modalities will be assessed relative to the clinical reference standard of genetic analysis of the fetus or phenotypic characterization and genetic analysis of the newborn.

Condition or disease
Trisomy 21

Layout table for study information
Study Type : Observational
Actual Enrollment : 18955 participants
Time Perspective: Prospective
Official Title: Non-invasive Chromosomal Examination of Trisomy
Study Start Date : March 2012
Actual Primary Completion Date : November 2013
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Down Syndrome

Patient with a trisomy 21 pregnancy confirmed by genetic testing.
Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.

Primary Outcome Measures :
  1. Difference in sensitivity and specificity of Ariosa Harmony™ Prenatal Test (AUCt) and combined first-trimester screening for detection of T21. [ Time Frame: Enrollment to delivery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women presenting for combined first trimester screening as part of routine prenatal care

Inclusion Criteria:

  1. Subject is at least 18 years old and can provide informed consent.
  2. Subject is planning a hospital delivery.
  3. Subject has a singleton pregnancy with a documented gestational age between 10 weeks, 0 days, and 14 weeks, 2 days, inclusive, at the time of the study blood sample collection.
  4. Subject is planning to undergo combined first trimester prenatal screening that includes NT measurement, and when indicated, serum screening with total or free β-hCG and PAPP-A.

Exclusion Criteria:

  1. Subject has known aneuploidy.
  2. Subject has active or history of malignancy requiring major surgery and/or systemic chemotherapy.
  3. Subject has a twin demise at any gestational age. Twin demise includes any reductions, spontaneous or elective, after sonographic identification of a second (or more) gestational sac. Any clinical, sonographic, or other testing that suggests twin demise would serve as an exclusion criterion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01511458

Show Show 36 study locations
Sponsors and Collaborators
Roche Sequencing Solutions
Perinatal Quality Foundation: Nuchal Translucency Quality Review
Layout table for investigator information
Principal Investigator: Mary E. Norton, MD Stanford University
Principal Investigator: Ronald Wapner, MD Columbia University

Additional Information:
American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, Sixth Edition, October 2007.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Roche Sequencing Solutions Identifier: NCT01511458    
Other Study ID Numbers: TD007
First Posted: January 18, 2012    Key Record Dates
Last Update Posted: July 14, 2014
Last Verified: July 2014
Keywords provided by Roche Sequencing Solutions:
Fetal aneuploidy
Trisomy 21
Down Syndrome
Prenatal screening
Non-invasive prenatal testing
First trimester
Combined screening
Nuchal translucency
cell free DNA
cf DNA
Performance characteristics of non-invasive first trimester screening
Harmony Prenatal Test
Additional relevant MeSH terms:
Layout table for MeSH terms
Down Syndrome
Chromosome Aberrations
Pathologic Processes
Chromosome Duplication
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn